Insider Buying: Precision BioSciences, Inc. (NASDAQ:DTIL) Director Buys $17,225.00 in Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) Director Geno J. Germano bought 3,250 shares of Precision BioSciences stock in a transaction dated Tuesday, March 25th. The stock was acquired at an average price of $5.30 per share, with a total value of $17,225.00. Following the acquisition, the director now directly owns 11,057 shares of the company’s stock, valued at approximately $58,602.10. This represents a 41.63 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Precision BioSciences Trading Up 3.5 %

Precision BioSciences stock opened at $4.70 on Friday. Precision BioSciences, Inc. has a 12 month low of $3.61 and a 12 month high of $15.97. The company has a quick ratio of 9.22, a current ratio of 9.22 and a debt-to-equity ratio of 0.34. The stock has a market cap of $36.05 million, a P/E ratio of 78.35 and a beta of 1.59. The company’s fifty day simple moving average is $5.11 and its 200-day simple moving average is $6.53.

Precision BioSciences (NASDAQ:DTIL) last issued its earnings results on Wednesday, March 26th. The company reported ($3.20) EPS for the quarter, missing analysts’ consensus estimates of ($2.09) by ($1.11). Precision BioSciences had a net margin of 11.48% and a negative return on equity of 23.69%. The firm had revenue of $3.47 million during the quarter, compared to analysts’ expectations of $4.28 million. As a group, sell-side analysts forecast that Precision BioSciences, Inc. will post -1.23 EPS for the current fiscal year.

Hedge Funds Weigh In On Precision BioSciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Commonwealth Equity Services LLC acquired a new position in shares of Precision BioSciences during the 4th quarter worth $48,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Precision BioSciences by 22.0% in the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 15,534 shares of the company’s stock worth $59,000 after purchasing an additional 2,805 shares in the last quarter. Samalin Investment Counsel LLC acquired a new position in Precision BioSciences during the fourth quarter worth $59,000. XTX Topco Ltd bought a new position in Precision BioSciences during the fourth quarter valued at about $67,000. Finally, Jane Street Group LLC bought a new position in Precision BioSciences during the fourth quarter valued at about $146,000. Institutional investors own 37.99% of the company’s stock.

Wall Street Analyst Weigh In

DTIL has been the subject of several research analyst reports. BMO Capital Markets raised Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 price objective for the company in a research note on Friday, January 10th. HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of Precision BioSciences in a research report on Friday.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.